Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company's initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. Its LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. The company is pre-revenue.
The Emeryville, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol LHDX. Lucira Health filed confidentially on November 23, 2020. BofA Securities, William Blair and LifeSci Capital are the joint bookrunners on the deal. No pricing terms were disclosed.
